PRIMECAP MANAGEMENT CO/CA/ - AXOVANT GENE THERAPIES LTD ownership

AXOVANT GENE THERAPIES LTD's ticker is AXGT and the CUSIP is G0750W203. A total of 44 filers reported holding AXOVANT GENE THERAPIES LTD in Q2 2020. The put-call ratio across all filers is 1.68 and the average weighting 0.1%.

Quarter-by-quarter ownership
PRIMECAP MANAGEMENT CO/CA/ ownership history of AXOVANT GENE THERAPIES LTD
ValueSharesWeighting
Q3 2020$246,000
+58.7%
53,225
-3.4%
0.00%
Q2 2020$155,000
-13.9%
55,125
-25.3%
0.00%
Q1 2020$180,000
-70.8%
73,825
-38.7%
0.00%
Q4 2019$617,000
-22.5%
120,425
-2.3%
0.00%
-100.0%
Q3 2019$796,000
+2.8%
123,287
-0.8%
0.00%0.0%
Q2 2019$774,000124,2870.00%
Other shareholders
AXOVANT GENE THERAPIES LTD shareholders Q2 2020
NameSharesValueWeighting ↓
DAFNA Capital Management LLC 1,021,566$2,493,0001.04%
SPHERA FUNDS MANAGEMENT LTD. 2,931,018$7,152,0000.90%
Consonance Capital Management LP 3,653,303$8,914,0000.66%
Rubric Capital Management LP 460,200$1,123,0000.18%
Hudson Bay Capital Management LP 1,350,000$3,294,0000.08%
Ikarian Capital, LLC 188,884$461,0000.04%
GSA CAPITAL PARTNERS LLP 41,037$100,0000.02%
Spark Investment Management LLC 18,072$44,0000.02%
Cable Hill Partners, LLC 15,000$37,0000.01%
BOOTHBAY FUND MANAGEMENT, LLC 38,800$95,0000.01%
View complete list of AXOVANT GENE THERAPIES LTD shareholders